CD274 and non-small cell lung carcinoma: Brahmer et al. showed the efficacy of anti-PD-L1 antibody (BMS-93655) in his multicenter phase 1 trial study with patients with advanced cancer, including non-small-cell lung cancer, melanoma and renal-cell cancer [20].